List view / Grid view
16 November 2012 | By Roche
The continued use of Avastin based therapy beyond first progression in metastatic colorectal cancer patients leads to survival benefits...
3 July 2012 | By FTI Consulting
The European Commission has adopted a legally binding decision in favour of granting of marketing authorisations for flutiform®...
25 June 2012 | By Abbott
Abbott announced that the CHMP has issued a positive opinion for HUMIRA®...
22 June 2012 | By Novartis
CHMP has adopted a positive opinion for Seebri® Breezhaler®...
22 June 2012 | By Novartis
Positive opinion for Afinitor® tablets...
22 June 2012 | By AstraZeneca
Zinforo receives positive CHMP opinion...
25 May 2012 | By Novo Nordisk
Novo Nordisk receives a positive opinion on recombinant factor XIII product (rFXIII)...
25 May 2012 | By GlaxoSmithKline
Positive opinion recommending marketing authorisation for Votrient®...
20 April 2012 | By Novartis
Upon approval, Jakavi(TM) (INC424, ruxolitinib) will be the first EU approved JAK inhibitor developed to treat patients with myelofibrosis, a rare blood cancer...
20 April 2012 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and AstraZeneca announced that the CHMP of the EMA has recommended approval of FORXIGA® (dapagliflozin) tablets...
17 February 2012 | By Novartis
CHMP concluded the risk-benefit review of Rasilez* (aliskiren)...
17 February 2012 | By GlaxoSmithKline
The EMA's CHMP has issued a positive opinion recommending marketing authorisation for Nimenrix® (MenACWY-TT)...
17 February 2012 | By Eli Lilly and Company
Patients in pivotal study achieved better glycemic control without weight gain...
17 February 2012 | By Abbott
Positive opinion based on supporting data from two Phase III clinical studies...
20 January 2012 | By Novartis
If approved, Signifor would be the first approved medication targeting Cushing's disease...
